NCT00219232View on ClinicalTrials.gov

An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

868

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions
Alzheimer's Disease
Interventions
DRUG

Rivastigmine Transdermal Patch

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY